keyword
https://read.qxmd.com/read/38536664/pharmacokinetics-of-subcutaneous-ketamine-administration-via-the-omnipod%C3%A2-system-in-dogs
#1
JOURNAL ARTICLE
Claudia Colón, Peter Early, Karen Muñana, Natasha Olby, Christopher Mariani, Shelby Mancini, Gilad Fefer, Zhong Li, Jessica Briley, Kate Bailey, Duncan Lascelles, Kristen Messenger
Ketamine is an injectable anesthetic agent with analgesic and antidepressant effects that can prevent maladaptive pain. Ketamine is metabolized by the liver into norketamine, an active metabolite. Prior rodent studies have suggested that norketamine is thought to contribute up to 30% of ketamine's analgesic effect. Ketamine is usually administered as an intravenous (IV) bolus injection or continuous rate infusion (CRI) but can be administered subcutaneously (SC) and intramuscularly (IM). The Omnipod® is a wireless, subcutaneous insulin delivery device that adheres to the skin and delivers insulin as an SC CRI...
March 27, 2024: Journal of Veterinary Pharmacology and Therapeutics
https://read.qxmd.com/read/38536431/enhancing-safety-in-tumescent-liposuction-managing-sedation-related-respiratory-issues-and-serious-complications-under-deep-sedation-with-the-propofol-ketamine-protocol
#2
JOURNAL ARTICLE
Eun Ju Kim, Hyunju Kim, Younchan Park
BACKGROUND: Over the past 4 years, aesthetic surgery, notably liposuction, has substantially increased. Tumescent liposuction, a popular technique, has two variants-true tumescent liposuction (TTL) and semi-tumescent liposuction. While TTL reduces risks, it has limitations. There is no literature reported on semi-tumescent liposuction under deep sedation using the propofol-ketamine protocol, which is proposed as a potentially safe alternative. METHODS: The retrospective analysis covered 8 years and included 3094 patients performed for tumescent liposuction under deep sedation, utilizing the propofol-ketamine protocol...
March 27, 2024: Aesthetic Plastic Surgery
https://read.qxmd.com/read/38533813/ketamine-butorphanol-medetomidine-for-the-immobilisation-of-free-living-hyenas-crocuta-crocuta
#3
JOURNAL ARTICLE
A Roug, L Meyer, L Netshitavhadulu, M Leiberich, P Buss
Free-ranging spotted hyenas (Crocuta crocuta) are immobilised for a variety of purposes, including wildlife-human conflict mitigation, research, and veterinary treatment. Combinations of tiletamine-zolazepam (Zoletil) and medetomidine are commonly used for immobilisation of hyenas, however, recovery times are long. In this descriptive study, a total of 20 adult or subadult free-ranging hyenas were immobilised near Skukuza in the Kruger National Park using ketamine, butorphanol, and medetomidine. The goal of the study was to evaluate a suitable dose and measure cardiorespiratory effects of this combination...
March 26, 2024: Journal of the South African Veterinary Association
https://read.qxmd.com/read/38533429/harmonising-iv-oxycodone-with-paediatric-perioperative-medications-a-compatibility-study-through-y-type-connectors
#4
JOURNAL ARTICLE
Souha H Youssef, Alka Garg, Yunmei Song, Nicole E Wylie, Sanjay Garg
PURPOSE: Co-administering multiple intravenous (IV) agents via Y-connectors is a common practice in hospitalised and fasting surgical patients. However, there is a lack of reliable data confirming the physical compatibility of some combinations including IV oxycodone, a drug that is gaining increasing popularity in the perioperative period. Concern regarding physical drug incompatibilities precludes concurrent coadministration with other common drugs through a single lumen. This can result in the cessation of infusions to allow the administration of other medications, resulting in exacerbation of acute pain...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38529445/rectal-sedation-with-ketamine-and-midazolam-in-the-management-of-uncooperative-children-during-dental-treatment-a-case-series-and-method-description
#5
JOURNAL ARTICLE
Hasan Alzoubi, Samar Kabbani, Ahmad Taleb, Nada Bshara, Mohamed K Altinawi, Mohammed Bashier Almonakel, Saleh Al Kurdi
Background In pediatric dentistry, sedation aims to eliminate anxiety to facilitate the completion of dental procedures. Sedation in children is a multidimensional field that includes the child, parents/guardians, and the health care team. The rectal route is generally painless, making it suitable for children who are afraid of needles. This route has several advantages over the oral route, including reduced patient cooperation requirements, a faster and more predictable onset, and less physical trauma than the intravenous and intramuscular routes...
February 2024: Curēus
https://read.qxmd.com/read/38526401/how-the-food-and-drug-administration-drug-approval-process-relates-to-the-potential-approval-of-intravenous-racemic-ketamine-for-treatment-resistant-major-depression
#6
JOURNAL ARTICLE
Sheldon H Preskorn
This column focuses on the status of intravenous racemic ketamine for the treatment of patients suffering from a form of major depressive disorder that does not respond to trials of currently available biogenic amine antidepressants. To provide context, the column reviews the 3 pivotal elements of the usual Food and Drug Administration (FDA) drug approval process: (1) the unmet medical need (ie, the indication) for which the drug is being developed, (2) the efficacy of the drug for that condition, and (3) the safety/tolerability of the drug...
March 1, 2024: Journal of Psychiatric Practice
https://read.qxmd.com/read/38526400/formulary-coverage-of-esketamine-and-ketamine-for-depression-in-ohio-health-insurance-marketplace-and-medicaid-plans
#7
REVIEW
Brian S Barnett
For more than 2 decades, intravenous ketamine has been demonstrated to have rapid antidepressant effects. However, access to this generic drug is limited due to insurers claiming it is "experimental" because ketamine does not have a Food and Drug Administration indication for depression. In contrast, intranasal esketamine, an enantiomer of ketamine, is approved by the Food and Drug Administration for depression and is still under patent. The goal of this column is to provide a clearer understanding of formulary coverage of these similar medications by insurers...
March 1, 2024: Journal of Psychiatric Practice
https://read.qxmd.com/read/38525254/hype-or-hope-high-placebo-response-in-major-depression-treatment-with-ketamine-and-esketamine-a-systematic-review-and-meta-analysis
#8
Alexandros Matsingos, Marcel Wilhelm, Laila Noor, Cüneyt Yildiz, Winfried Rief, Stefan G Hofmann, Irina Falkenberg, Tilo Kircher
BACKGROUND: Ketamine and esketamine offer a novel approach in the pharmacological treatment of major depressive disorder (MDD). This meta-analysis aimed to investigate the placebo response in double-blind, randomized controlled studies (RCTs) on patients with MDD receiving ketamine or esketamine. METHODS: For this systematic review and meta-analysis Medline (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), PsycInfo and Embase databases were systematically searched for citations published up to March 17, 2023...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38524955/concerns-on-the-use-of-ketamine-in-the-treatment-of-depression
#9
JOURNAL ARTICLE
Amiya K Barik, Rajeev Chauhan, Ashwini Reddy, Narender Kaloria
No abstract text is available yet for this article.
January 2024: Indian Journal of Psychological Medicine
https://read.qxmd.com/read/38523183/oral-esketamine-in-patients-with-treatment-resistant-depression-a-double-blind-randomized-placebo-controlled-trial-with-open-label-extension
#10
JOURNAL ARTICLE
Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis, Jan Spijker, Annemarie van der Meij, Antoinette D I van Asselt, Marije Aan Het Rot, Robert A Schoevers
About one-third of patients with depression do not achieve adequate response to current treatment options. Although intravenous and intranasal administrations of (es)ketamine have shown antidepressant properties, their accessibility and scalability are limited. We investigated the efficacy, safety, and tolerability of generic oral esketamine in patients with treatment-resistant depression (TRD) in a randomized placebo-controlled trial with open-label extension. This study consisted of 1) a six-week fixed low-dose treatment phase during which 111 participants received oral esketamine 30 mg or placebo three times a day; 2) a four-week wash-out phase; and 3) an optional six-week open-label individually titrated treatment phase during which participants received 0...
March 25, 2024: Molecular Psychiatry
https://read.qxmd.com/read/38523035/ketamine-intolerance-in-patients-on-enhanced-recovery-after-surgery-protocols-undergoing-colorectal-operations
#11
JOURNAL ARTICLE
Sarah B Stringfield, Anthony C Waddimba, Keirsyn M Criss, Brooke Burgess, Luke J Dosselman, Alessandro Fichera, Katerina O Wells, James Fleshman
BACKGROUND: Ketamine is used in enhanced recovery after surgery (ERAS) protocols because of its beneficial antihyperalgesic and antitolerance effects. However, adverse effects such as hallucinations, sedation, and diplopia could limit ketamine's utility. The main objective of this study was to identify rates of ketamine side effects in postoperative patients after colorectal surgery and, secondarily, to compare short-term outcomes between patients receiving ketamine analgesia and controls...
February 28, 2024: Journal of Gastrointestinal Surgery
https://read.qxmd.com/read/38522166/oral-prolonged-release-ketamine-in-treatment-resistant-depression-a-double-blind-randomized-placebo-controlled-multicentre-trial-of-ket01-a-novel-ketamine-formulation-clinical-and-safety-results
#12
JOURNAL ARTICLE
M Colla, B Offenhammer, H Scheerer, G Kronenberg, S Vetter, J Mutschler, T Mikoteit, A Bankwitz, A Adank, L Schaekel, C Eicher, A B Brühl, E Seifritz
INTRODUCTION: We investigated the antidepressant effects of a novel oral prolonged-release formulation of racemic ketamine (KET01) in patients suffering from treatment-resistant depression (TRD) as add-on therapy. MATERIAL AND METHODS: Patients were randomized to an additional 160 mg/day or 240 mg/day KET01 or placebo for 14 days. The primary endpoint was change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to day 15. For treatment group comparisons, we used ANOVA with pairwise least squares mean difference tests in a mixed model repeated measures analysis...
March 4, 2024: Journal of Psychiatric Research
https://read.qxmd.com/read/38522144/effects-of-esketamine-on-postoperative-negative-emotions-and-early-cognitive-disorders-in-patients-undergoing-non-cardiac-thoracic-surgery-a-randomized-controlled-trial
#13
JOURNAL ARTICLE
Tianyuan Luo, Zhimin Deng, Qiyang Ren, Fangfang Mu, You Zhang, Haiying Wang
STUDY OBJECTIVE: To investigate whether a single dosage of esketamine injection in the anesthesia period could improve postoperative negative emotions and early cognitive function in patients undergoing non-cardiac thoracic surgery. DESIGN: A prospective single center double blinded randomized placebo-controlled trial. SETTING: Perioperative period; operating room, post anesthesia care unit and hospital ward. PATIENTS: 129 adult patients that underwent elective non-cardiac thoracic surgery under general anesthesia...
March 23, 2024: Journal of Clinical Anesthesia
https://read.qxmd.com/read/38519818/stimulus-mediation-specificity-and-impact-of-menthol-in-rats-trained-to-discriminate-puffs-of-nicotine-e-cigarette-aerosol-from-nicotine-free-aerosol
#14
JOURNAL ARTICLE
Yasmin Alkhlaif, Keith L Shelton
RATIONALE: It is unclear if e-cigarettes have reduced abuse liability relative to traditional cigarettes, especially when considering advanced devices which deliver nicotine more efficiently. Translatable and predictive animal models are needed to addresses this question. OBJECTIVES: Our goal was to explore the subjective stimulus effects of e-cigarettes by training rats to discriminate puffs of nicotine aerosol from vehicle aerosol using an aerosol delivery system designed to model e-cigarette use patterns in humans...
March 23, 2024: Psychopharmacology
https://read.qxmd.com/read/38519542/ketamine-is-in-the-spotlight-thanks-to-elon-musk-but-is-it-the-right-treatment-for-depression
#15
David Adam
No abstract text is available yet for this article.
March 20, 2024: Nature
https://read.qxmd.com/read/38518518/iv-low-dose-ketamine-infusions-for-treatment-resistant-depression-results-from-a-five-year-study-at-a-free-public-clinic-in-an-academic-hospital
#16
JOURNAL ARTICLE
Gilmar Gutierrez, Melody J Y Kang, Gustavo Vazquez
Individuals with major depressive disorder and treatment resistant depression (MDD-TRD) have limited and sometimes poorly tolerated therapeutic options. Low dose ketamine has presented promising and potent antidepressant effects in this population. To support the existent literature, we conducted a longitudinal study examining five years of real-world clinical data on the use of IV low-dose ketamine alongside standard care for MDD-TRD outpatients. For this study we collected demographic information, clinical scale scores, side effects and dropout data...
March 19, 2024: Psychiatry Research
https://read.qxmd.com/read/38518457/a-combined-toxicokinetic-and-metabolic-approach-to-investigate-deschloro-n-ethylketamine-exposure-in-a-multidrug-user
#17
JOURNAL ARTICLE
Romain Magny, Bruno Mégarbane, Lucie Chevillard, Emmanuel Roulland, Benoit Bardèche-Trystram, Véronique Dumestre-Toulet, Laurence Labat, Pascal Houzé
The use of new psychoactive substances derived from ketamine is rarely reported in France. A chronic GHB, 3-MMC, and methoxetamine consumer presented a loss of consciousness in a chemsex context and was referred to the intensive care unit with a rapid and favorable outcome. To investigate the chemicals responsible for the intoxication, a comprehensive analysis was conducted on the ten plasma samples collected over a 29.5-hour period, urine obtained upon admission, a 2-cm hair strand sample, and a seized crystal...
March 13, 2024: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/38518272/psychedelic-therapy-a-primer-for-primary-care-clinicians-ketamine
#18
JOURNAL ARTICLE
Viviana D Evans, Alejandro Arenas, Kenneth Shinozuka, Burton J Tabaac, Bryce D Beutler, Kirsten Cherian, Chelsey Fasano, Owen S Muir
BACKGROUND: Ketamine, an arylcyclohexylamine dissociative anesthetic agent, has evolved into a versatile therapeutic. It has a rapid-onset, well-understood cardiovascular effects and a favorable safety profile in clinical use. Its enantiomeric compound, esketamine, was approved by the Food and Drug Administration in 2019 for both treatment-resistant depression and major depressive disorder with suicidal ideation. AREAS OF UNCERTAINTY: Research indicates dose-dependent impacts on cognition, particularly affecting episodic and working memory following both acute administration and chronic use, albeit temporarily for the former and potentially persistent for the latter...
March 2024: American Journal of Therapeutics
https://read.qxmd.com/read/38518269/psychedelic-therapy-a-primer-for-primary-care-clinicians-psilocybin
#19
JOURNAL ARTICLE
Burton J Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir
BACKGROUND: The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT2A receptor. This review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. AREAS OF UNCERTAINTY: Despite initial concerns that psilocybin could cause psychosis, contemporary research has demonstrated that psilocybin is generally safe. The most common adverse effects are nausea and headache, yet both tend to be transient...
March 2024: American Journal of Therapeutics
https://read.qxmd.com/read/38518266/psychedelic-therapy-a-primer-for-primary-care-clinicians-historical-perspective-and-overview
#20
JOURNAL ARTICLE
Burton J Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir
BACKGROUND: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including those that are treatment-resistent. The latter half of the 20th century marked a revolution in the treatment of mental illnesses, exemplified by the introduction of selective serotonin reuptake inhibitors and other pharmacological agents. Nevertheless, mental illness remains a major public health crisis, affecting nearly one billion individuals worldwide...
March 2024: American Journal of Therapeutics
keyword
keyword
181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.